EN
Spanish Japanese Chinese

New Brunswick-based Johnson & Johnson Working to Supply One Billion Doses of COVID-19 Vaccine Worldwide

As part of a landmark partnership, Johnson & Johnson has announced a multi-tiered strategy in combating the global spread of COVID-19.

Based in New Brunswick, the world’s largest and most broadly-based health care company has jointly pledged $1 billion of investment to co-fund research, development and clinical testing in pursuit of a COVID-19 vaccine. This is through a new partnership with Biomedical Advanced Research and Development Authority (or BARDA) which is part of the U.S. Department of Health and Human Services. Johnson & Johnson is also expanding its global manufacturing capacity through the establishment of new U.S. vaccine manufacturing capabilities and increasing capacity in other countries. This will assist in the rapid production of a vaccine and will enable the supply of more than one billion doses of a safe and effective vaccine globally. The company is committed to bringing an affordable vaccine to the public on a not-for-profit basis for emergency pandemic use.

The company is aiming to initiate a Phase 1 clinical study in September 2020, with clinical data on safety expected to be available by the end of the year. This could allow vaccine availability for emergency use in early 2021. By comparison the typical vaccine development process involves a number of different research stages spanning 5 to 7 years.

For more information on Johnson & Johnson’s approach to combating the pandemic, visit www.jnj.com/coronavirus.